Form 4: Broadwood Partners Acquires Significant Stake in Oncocyte Corp Through Direct Offering and Private Placement

Broadwood Partners, L.P. acquires over 5 million shares of Oncocyte Corp common stock through a direct offering and private placement, becoming a 10% owner.

Summary

• Broadwood Partners, L.P., along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Oncocyte Corp [OCX] securities.
• On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation to acquire shares of common stock.
• Broadwood Partners acquired 660,207 shares in a registered direct offering at $2.05 per share, totaling $1,353,424.
• Additionally, Broadwood Partners acquired 4,505,488 shares in a private placement at $2.05 per share, totaling $9,236,250.
• Following these transactions, Broadwood Partners directly owns 6,904,612 shares and 11,410,100 shares of Oncocyte Corp common stock.
• Neal C. Bradsher also directly owns 157 shares.
• Broadwood Partners also holds warrants to purchase 150,093 shares of common stock, exercisable at $30.6, expiring on April 19, 2027.
• The filing indicates Broadwood Partners and related parties now hold over 10% ownership in Oncocyte Corp.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant investment is being made in the company, indicating confidence from Broadwood Partners. However, the document is purely transactional and lacks broader context.

Positives

• Broadwood Partners' significant investment signals confidence in Oncocyte Corp's future prospects.
• The acquisition of shares through both a direct offering and private placement suggests a strong commitment.
• The warrants held by Broadwood Partners could provide additional capital to Oncocyte Corp if exercised.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but the investment's success depends on Oncocyte Corp's performance.
• The high exercise price of the warrants ($30.6) may make them less likely to be exercised unless Oncocyte Corp's stock price increases substantially.

Future Outlook

The document does not contain explicit forward-looking statements from Oncocyte Corp. The future outlook depends on Oncocyte's performance and Broadwood Partners' investment strategy.

Industry Context

This announcement reflects investment activity in the biotechnology/healthcare sector. Monitoring similar investments in comparable companies would provide further context.

Stakeholder Impact

• Shareholders may view the investment positively, potentially leading to increased stock value.
• The investment provides Oncocyte Corp with additional capital, potentially supporting research and development or other strategic initiatives.

Key Dates

Keywords

Oncocyte Corp, Broadwood Partners, Securities Purchase Agreement, Direct Offering, Private Placement, Beneficial Ownership, Form 4, OCX, Warrants